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Background: Myasthenia gravis is an autoimmune neuromuscular disorder character-
ized by the production of abnormal autoantibodies directed against the receptors present 
in the neuromuscular junction. It has been the standard practice to offer thymectomy in 
all generalized myasthenia gravis patients despite the lack of robust evidence.
Objectives: The objectives of this study are to describe the clinical profile and differen-
tiate the clinical outcomes of thymectomy versus non-thymectomy and thymomatous 
versus non-thymomatous myasthenia gravis patients in the Philippine General Hospital.
Methodology: Between 2009 and 2014, a total of 69 postthymectomy and 16 
non-thymectomy patient records were successfully retrieved. The demographic char-
acteristics, surgical approach, and histopathologic results were obtained. The clinical 
outcome after 6 months or 1 year-follow-up was also determined and grouped accord-
ing to the following: (1) complete remission, (2) pharmacological remission, (3) no clinical 
change, (4) worsening symptoms, and (5) mortality.
results: Majority of the patients were females (68.0%) with a mean age of 39.8 years 
and a mean duration of myasthenic symptoms of 21 months. Using the Myasthenia 
Gravis Foundation of America classification, 54.1% of patients fell under Class II and 
48.2% of them presented with generalized weakness. In this study, 60.8% of post-
thymectomy myasthenia gravis patients had either complete remission or pharmacologic 
remission compared with 12.5% among non-thymectomy patients (p-value <0.001). 
No significant difference in the clinical outcome was found between thymomatous and 
non- thymomatous myasthenia gravis after thymectomy (p-value = 0.29).
conclusion: This study showed that both thymomatous and non-thymomatous myas-
thenia gravis patients who underwent thymectomy had a higher incidence of complete 
stable remission and pharmacologic remission as compared with myasthenia gravis 
patients who did not undergo thymectomy.
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BacKgrOUnD
Myasthenia gravis is an autoimmune neuromuscular disorder 
characterized by the production of abnormal autoantibodies 
directed against nicotinic acetylcholine receptors (AChR) present 
in the neuromuscular junctions. It presents with weakness of vol-
untary ocular, bulbar, and limb muscles, and in severe cases, death 
from difficulty of breathing (1, 2). In a large epidemiological study 
done within a 60-year period, the pooled incidence of myasthenia 
gravis is 5.3 per million person years with a prevalence rate of 15 
times higher probably attributable to the good survival and low 
mortality of the disease (3).
The pathogenesis of myasthenia gravis is due to the pres-
ence of antibodies significantly interfering the neuromuscular 
junction. Antibodies against the AChR and the muscle specific 
kinase (MuSK) are the two major types of antibodies found (4). 
Anti-AChR is postulated to accelerate degradation of AChR, 
functionally block the acetylcholine binding sites, and cause 
complement-mediated damage of the postsynaptic membrane. 
On the other hand, anti-MuSK inhibits the clustering of AChR 
on the postsynaptic membrane causing the increased muscle 
fatigability (5).
The treatment of myasthenia gravis is geared toward improv-
ing the neuromuscular transmission, interfering with the 
antibodies, and modifying the natural history of the disease (5). 
Acetylcholineserase inhibitors, such as pyridostigmine, prolong 
the availability of acetylcholine in the neuromuscular junction 
and are regarded as the first-line treatment for myasthenia gravis 
(6). Steroids, usually prednisone, are added in the chronic thera-
peutic regimen of myasthenia gravis patients. Its effective immu-
nosuppressive activity provides clinical benefit in about 80% of 
the patients (7). Several other immunosuppressive agents, such 
as azathioprine, cyclosporin A, cyclophosphamide, mycopheno-
late mofetil, and methotrexate, are used as an alternative or in 
combination with steroids; however, their efficacy are yet to be 
established by well-designed clinical trials. In some patients on 
whom rapid effect is warranted, intravenous immune globulin 
and plasmapheresis act as rapid immunotherapeutic options (8). 
It has been the practice to offer thymectomy in all myasthenia 
gravis patients, especially to those who are younger than 60 years 
old and with generalized symptoms, even if its efficacy in improv-
ing outcomes is still under study (9). Theoretically, thymectomy 
may eliminate the source of autoantigens, remove the B cell reser-
voir secreting antibodies, and correct the disturbance of immune 
regulation (10). In a study by Blalock et al., complete resolution of 
symptoms in thymomatous myasthenia gravis was first found in a 
21-year-old female after thymectomy (11). In another study, there 
was also improvement even in non-thymomatous myasthenia 
gravis postthymectomy (12). Most studies have shown higher 
remission rates from 13 to 46% in symptomatic patients under-
going thymectomy compared with those who were treated only 
pharmacologically (13–15). However, the role of thymectomy is 
still uncertain and the available studies still have inconclusive 
results in the efficacy, indication, and timing for thymectomy 
between thymomatous and non-thymomatous myasthenia gravis 
(16, 17). In the Philippines, the present consensus recommends 
thymectomy as an option to increase the likelihood of remission 
between thymomatous and non-thymomatous myasthenia gravis 
patients until randomized controlled trials become available (18).
raTiOnale anD OBJecTiVes
The primary objective of this study is to compare the clinical out-
come of myasthenia gravis patients who underwent thymectomy 
versus those who did not undergo thymectomy. This study also 
aims to describe the clinical profile of patients with myasthenia 
gravis and to determine the clinical outcome of thymomatous 
versus non-thymomatous myasthenia gravis after thymectomy. 
Knowing their outcomes could help us in the selection of patients 
whom thymectomy could be appropriately offered in the future.
MeThODOlOgY
study Design and study Population
This is a 6-year retrospective cohort study from January 2009 
to December 2014. The medical records of all myasthenia 
gravis patients admitted in the charity wards were obtained and 
reviewed. The list of 149 patients who underwent thymectomy was 
obtained from the database of the Thoracic and Cardiovascular 
Surgery section, whereas the list of 27 myasthenia gravis patients 
who did not undergo thymectomy was obtained from the Adult 
Neurology section electronic census of charity inpatients. The lists 
were submitted to the Medical Records Section for retrieval. All 
recoverable medical records of adult myasthenia gravis patients 
aged more than 18 years of age were included in the study. Missing 
records were excluded.
Data collection
The age, sex, comorbidities, onset and duration of symptoms, 
characteristics of symptoms, and medications were recorded. The 
myasthenia gravis severity was evaluated using the Myasthenia 
Gravis Foundation of America (MGFA) classification. The clinical 
outcome of patients with myasthenia gravis who did not undergo 
thymectomy was reviewed after 6 months or 1 year of starting 
pharmacologic treatment, depending on the available follow-up 
data. The clinical outcome was grouped according to the follow-
ing: (1) complete remission, (2) pharmacological remission, (3) 
no clinical change, (4) worsening symptoms, and (5) mortality. 
The preoperative characteristics, surgical approach, histopatho-
logic results, and clinical outcomes on the sixth month or 1-year 
postoperative follow-up of those who underwent thymectomy 
were also reviewed. All final histopathologic results were obtained 
from the Surgical Pathology Unit of the Department of Pathology. 
Patients who had no follow-up data were contacted through voice 
call to determine their clinical outcome.
study analysis
These data were encoded using Microsoft Excel and analyzed 
using the Microsoft Excel Data analysis toolpack and the Epi-
Info 7.0 program. The difference in the clinical outcome of 
postthymectomy patients versus patients who did not undergo 
thymectomy was analyzed using the Fisher’s exact test. The dif-
ference between thymomatous and non-thymomatous groups 
TaBle 1 | Other indications for thymectomy other than myasthenia 
gravis.
number (%)
Thymoma without myasthenia gravis 35 (29.7)
Metastasis 3 (2.5)
Germ cell tumor 5 (4.2)
Tuberculosis 1 (0.8)
Others (cysts, lymphoma) 5 (4.2)
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among postthymectomy patients was also analyzed using the 
Fisher’s exact test.
Definition of Terms
 (1) Prolonged intubation – defined as difficulty weaning off the 
mechanical ventilator after ≥14 days.
 (2) Complete stable remission  –  corresponds to the state when 
the patient does not have symptoms anymore even with no 
medications for a period of at least 6 months.
 (3) Pharmacologic remission  –  corresponds to at least 50% 
decrease in the need of medications to control the symptoms 
of myasthenia gravis.
 (4) Worse symptoms  –  defined as any amount of increase in 
the need for medications in order to control the myasthenic 
symptoms.
 (5) Good response – corresponds to either complete stable remis-
sion or pharmacologic remission.
 (6) Poor response – corresponds to whether the patient had no 
clinical change, worse symptoms, or died within the follow-up 
period.
ethical considerations
This study was submitted and approved by the University of 
the Philippines Manila Research Ethics Board Panel. The data 
collection commenced upon approval from the panel and the 
anonymity of subjects, as well as the confidentiality of the data 
obtained, was assured by the researcher.
resUlTs
A total of 134 out of the 176 patient records (71.1%) were success-
fully retrieved from the Medical Records section. Among those 
who underwent thymectomy, 118 out of the 149 patient records 
were obtained. Only 69 (58.5%) patients were found to have 
myasthenia gravis, and the other patients underwent thymectomy 
for other indications (Table 1). Out of the 27 myasthenia gravis 
inpatients who did not undergo thymectomy, only 16 patient 
records were retrieved. The 42 missing records from both lists 
were excluded in the study.
The age of all the myasthenia gravis patients included in this 
study ranges from 18 to 69 years with a mean age of 39.8 years 
in both the postthymectomy and non-thymectomy patients. 
Majority of the patients were females (68.0%). It was also found 
that 86.0 and 66.0% of the female and male patients, respectively, 
had symptoms before the age of 50 years. The mean duration of 
myasthenia gravis symptoms was 21 months where most of the 
patients presented with generalized weakness (48.2%), followed 
by ocular symptoms reported as ptosis and/or diplopia in 47.1%, 
and bulbar symptoms described as dysphagia in 34.1% of the 
patients. Fifteen patients (17.6%) had pure ocular symptoms 
while only three (3.5%) were presented with dominant bulbar 
symptoms. Using the MGFA classification, more than half of the 
patients had mild symptoms (IIa = 16.5%, IIb = 37.6%), while 14 
(IIIa = 3.5%, IIIb = 12.9%) and 3 (IVa = 0%, IVb = 3.5%) had 
moderate and severe symptoms, respectively. Only a small pro-
portion of the patients (15.3%) necessitated prolonged intubation 
usually due to complications of pneumonia. Pyridostigmine and 
prednisone were the mainstay therapy for 70.6% of the patients. 
Table 2 shows the baseline characteristics of all the myasthenia 
gravis patients included in the study.
Three out of the 85 included patients had no follow-up record. 
In this study, it was found that 60.8% of postthymectomy myas-
thenia gravis patients had good outcome compared with 12.5% of 
the non-thymectomy patients after at least 6 months of follow-up 
(p-value <0.001). Among the 67 postthymectomy patients, those 
who presented with good outcome mostly presented with mild 
symptoms (83.3%) before thymectomy. Even most of the patients 
with pure ocular myasthenia gravis (60.0%) were found to have 
clinical improvement after thymectomy. Majority of the patients 
with poor outcome had onset of symptoms before the age of 
50 years (p-value = 0.55) and four of them died because of comor-
bid complications such as pneumonia, pulmonary embolism, and 
arrhythmia. Among those who did not undergo thymectomy, 
81.2% of patients had poor outcome within 6 months to 1 year 
of follow-up and none of them achieved complete myasthenia 
gravis remission. Table 3 summarizes the clinical outcome of the 
myasthenia gravis patients included in the study.
Among the postthymectomy patients, majority underwent 
median sternotomy (86.2%) while only a small proportion of 
patients underwent video-assisted thoracoscopic thymectomy 
(13.8%). It was also found that 29 (42.0%) were thymomatous 
by histopathologic diagnosis, most of which was classified 
as Thymoma Type B (18.7%) based on the World Health 
Organization (WHO) classification of thymoma. Another 29 
(42.0%) were non-thymomatous, majority of which were thymic 
lymphoproliferative tumor (Table 4). A total of 11 patients had no 
histopathologic record available from the Surgical Histopathologic 
Unit of the Philippine General Hospital. Non-thymomatous 
myasthenia gravis patients were found to have longer duration of 
preoperative symptoms (33.8 months) but tend to have shorter 
hospital stay (8.4 days) compared with thymomatous myasthenia 
gravis. Moreover, non-thymomatous myasthenia gravis had 
higher percentage with good outcome (62.1%, p-value =  0.29) 
compared with thymomatous myasthenia gravis (51.7%) and 
tended to have shorter duration of hospital stay ranging from 1 
to 34 days (Table 5).
DiscUssiOn
This study determined the clinical profile and outcome of myas-
thenia patients in our institution. Most of the myasthenia patients 
were young females aged <50  years old. This finding was also 
observed in a recent epidemiological study in Taiwan consisting 
of 5,211 patients where 60.7% were females in the 15–54 age 
TaBle 4 | histopathologic diagnosis of postthymectomy patients.
histopathologic results (n = 69) number (%)
Thymic hyperplasia 17 (24.6)
Thymoma
Type A 6 (8.7)
Type AB 6 (8.7)
Type B1 4 (5.8)
Type B2 2 (2.8)
Type B3 7 (10.1)
Type C 4 (5.8)
Others 8 (11.6)
Histologically unremarkable thymic tissue 4 (5.8)
No histopathologic results 11 (15.9)
TaBle 3 | clinical outcomes of postthymectomy patients versus 









10 14.5 0 0.0
Pharmacological 
remission
32 46.3 2 12.5
No clinical change 12 17.4 6 37.5
Worse symptoms 9 13.0 2 12.5
Mortality 4 5.8 5 31.2
No follow-up record 2 2.96 1 6.2
TaBle 2 | Baseline characteristics of myasthenia gravis patients included in the study.
Baseline characteristics Postthymectomy (n = 69) non-thymectomy (n = 16) Total (n = 85)
Age 40.2 ± 13.1 38.1 ± 12.5 39.8 ± 12.9
Gender
Male 23 (33.3) 4 (25.0) 27 (32.0)
Female 46 (66.6) 12 (75) 58 (68.0)
Age at presentation 38.4 ± 13.8 35.4 ± 12.4 37.6 ± 13.5
<30 years old 19 (27.5) 6 (37.5) 25 (29.4)
31–50 years old 27 (39.1) 6 (37.5) 33 (38.8)
>50 years old 23 (33.3) 4 (20.0) 27 (31.8)
Comorbidities
None 38 (55.1) 4 (25.0) 42 (49.4)
Pneumonia 16 (23.2) 10 (62.5) 26 (30.6)
Goiter 5 (7.2) 2 (12.5) 7 (8.2)
Hypertension 8 (11.6) 3 (18.7) 11 (12.9)
Diabetes mellitus 3 (4.3) 1 (6.2) 4 (4.7)
Others 3 (4.3) 5 (31.2) 8 (9.4)
Myasthenia gravis symptoms
Ocular 34 (49.3) 6 (37.5) 40 (47.1)
Bulbar 24 (34.8) 5 (31.2) 29 (34.1)
Generalized 31 (44.9) 10 (62.5) 41 (48.2)
Duration of symptoms (range: 0.3–144.0 months) 21.2 ± 26.5 22.5 ± 28.2 21.5 ± 26.7 
Pharmacologic treatment
Pyridostigmine 12 (17.4) 1 (6.2) 13 (15.3)
Pyridostigmine + prednisone 47 (68.1) 13 (81.2) 60 (70.6)
Pyridostigmine + azathioprine 2 (2.9) 1 (6.2) 3 (3.5)
≥3 drugs 8 (11.6) 1 (6.2) 9 (10.6)
MGFA classification
I 14 (20.3) 1 (6.2) 15 (17.6)
II 39 (56.5) 7 (43.7) 46 (54.1)
III 11 (15.9) 3 (18.7) 14 (16.5)
IV 3 (4.3) 0 (0.0) 3 (3.5)
V 2 (2.9) 5 (31.2) 7 (8.2)
Prolonged intubation
Yes 9 (13.0) 4 (25.0) 13 (15.3)
No 60 (87.0) 12 (75.0) 72 (84.7)
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group (19). The higher percentage of females <50 years old and 
males >50 years old may be reflective of the usual bimodal pat-
tern of myasthenia gravis where it first peaks in the third decade 
among females and then in the sixth decade among males (20). 
The MGFA classification was designed to uniformly classify 
myasthenia gravis despite the subjective nature of the disease and 
is usually utilized to determine its severity (21). Around 54.0% 
of the patients fell under Class II corresponding to mild symp-
toms. Also, about half of the patients presented with generalized 
weakness. This is so probably because most of the patients sought 
consult when the generalization of myasthenia gravis sets in, 
which usually occurs within the first 2 years of the disease (22). 
Even if majority of patients initially present with ocular symp-
toms, studies have shown that approximately 50% of patients 
progress to generalized myasthenia gravis in their lifetime (23). 
In 70.6% of the patients, the combination of pyridostigmine and 
prednisone were the therapeutic mainstay. Although previous 
studies have shown that most myasthenia gravis patients were 
TaBle 5 | clinical outcomes of thymomatous versus non-thymomatous myasthenia gravis after 6 months and/or 1 year postthymectomy.
Thymomatous (n = 29) % non-thymomatous (n = 29) %
Age
<30 years old 2 6.9 16 55.2
30–50 years old 20 69.0 8 27.6
>50 years old 7 24.1 5 17.2
Surgical approach
Median sternotomy 25 86.2 25 86.2
Video-assisted thoracoscopy 4 13.8 4 13.8
Preoperative duration of symptoms 18.3 months (range: 1–60 months) 33.8 months (range: 0.3–144 months)
Duration of confinement 15.8 days (range: 2–85 days) 8.4 days (range: 1–34 days)
Good outcome 15 51.7 18 62.1
Poor outcome 13 44.8 10 34.5
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solely maintained on anticholinesterase inhibitor and only about 
one-fourth of patients necessitated combination with steroids, 
it was found to be more sufficient to give combination therapy 
especially in generalized myasthenia gravis (24, 25).
Thymectomy is currently a recommended treatment option in 
myasthenia gravis even in the absence of randomized controlled 
trials showing its benefits (18). Different surgical approaches 
are available, ranging from extended transsternal thymectomy 
to minimally invasive video-assisted thoracosopic surgery to 
the newly developed robotic surgery (26). In this study, most 
patients underwent median sternotomy, and only a small 
proportion underwent video-assisted thoracoscopic surgery. 
Yet, none underwent robotic surgery. In a study by Zahid 
et  al., video-assisted thoracoscopic surgery was found to have 
no statistically significant difference in terms of remission and 
recurrence rates compared with median sternotomy. However, 
patients were found to have shorter hospital stay, lesser blood 
loss, and greater cosmetic satisfaction (27). An 18-month lag 
from the time of symptom development to surgery was found 
among thymomatous myasthenia gravis, which is shorter than 
that of non-thymomatous myasthenia gravis. This duration was 
longer than that in literature, and this difference may suggest that 
thymectomy is probably not readily offered in non-thymomatous 
myasthenia gravis until it was observed that symptoms does not 
resolve even with medications (24).
In this study, postthymectomy patients were shown to have 
statistically significant higher percentage with complete stable 
remission and pharmacologic remission compared with patients 
who did not undergo surgery. This finding is in line with that 
of previous literature where remission or reduction in medica-
tion was found in approximately 70% of the myasthenia gravis 
patients after thymectomy (28). This was also elucidated in a 
previous local study consisting of 10 myasthenia gravis patients 
who had clinical improvement after thymectomy (29). Also, it was 
found that myasthenia gravis with mild severity, including those 
with pure ocular involvement, seems to have better outcome and 
higher remission rate, which is consistent with previous studies 
(24, 30–32). Poor outcome after thymectomy was seen more fre-
quently in patients whose myasthenia gravis symptoms occurred 
before the age of 50 years. This finding supports an earlier study 
that thymectomy may be done and even be of benefit in patients 
with late-onset myasthenia gravis (age >50 years) (33).
This study also showed that there is no difference in the 
clinical outcome of thymomatous myasthenia gravis as com-
pared with that of non-thymomatous in histology. Thymomatous 
myasthenia is an absolute indication for thymectomy with an 
approximately 50% increase in survival at 5  years (34). In this 
study, thymoma accounts for 34.1% of myasthenia gravis patients, 
and this is higher from previous literature of 15% (35). Despite 
the established benefit of thymectomy in thymomatous myas-
thenia gravis, there are studies showing an even better clinical 
outcome in non-thymomatous myasthenia gravis as compared 
with thymomatous myasthenia gravis after thymectomy (28, 35, 
36). This is postulated because of the presence of titin and another 
autoantibody to the RyR channel of the sarcoplasmic reticulum in 
patients with thymoma, which is associated to an increase of the 
severity of myasthenia gravis (37).
liMiTaTiOns
This study had several limitations. Only 71% of the patient records 
were obtained and this relatively low retrieval rate was because 
of the manual filing in the Medical Records section, which is 
prone to chart loss and misplacement. The missing records may 
actually change the results of this study. Moreover, the selection 
of patients was based on the available patient database in our 
institution. Since only inpatients were included, this means that 
they were admitted either because they underwent surgery or 
because they were sick requiring medical management. This may 
also be the reason why majority of patients already presented with 
generalized symptoms. Also, the determination of the patient 
clinical outcomes were only based on record review and voice 
call, hence, underreporting was a possibility. Lastly, a definitive 
conclusion cannot be made between the groups compared in this 
study because the baseline characteristics of the patients were not 
similar throughout the duration of the study.
cOnclUsiOn
In summary, this study showed that both thymomatous and 
non-thymomatous myasthenia gravis patients who underwent 
thymectomy had a higher prevalence of complete stable remis-
sion and pharmacologic remission as compared with myasthenia 
gravis patients who did not undergo thymectomy. Although a 
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definite conclusion cannot be made due to the inherent limita-
tions of this study, it may just be acceptable to offer this option 
especially when generalized weakness is already evident.
recOMMenDaTiOns
The authors strongly recommend an electronic myasthenia gravis 
patient registry in our institution and even in the national level 
in order to ensure complete inclusion of patients in future studies. 
Also, a study including outpatients is highly recommended, so 
that a more generalizable picture of myasthenia gravis patients 
in the local setting may be obtained. A long-term follow-up 
is also recommended.
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